A Web-Based Cognitive Behavior Therapy Intervention to Improve Social and Occupational Functioning in Adults With Type 2 Diabetes (The SpringboarD Trial): Randomized Controlled Trial.
depression
internet
type 2 diabetes
Journal
Journal of medical Internet research
ISSN: 1438-8871
Titre abrégé: J Med Internet Res
Pays: Canada
ID NLM: 100959882
Informations de publication
Date de publication:
21 05 2019
21 05 2019
Historique:
received:
19
09
2018
accepted:
12
12
2018
revised:
11
12
2018
entrez:
23
5
2019
pubmed:
23
5
2019
medline:
15
2
2020
Statut:
epublish
Résumé
Depressive symptoms are common in people with type 2 diabetes mellitus (T2DM). Effective depression treatments exist; however, access to psychological support is characteristically low. Web-based cognitive behavioral therapy (CBT) is accessible, nonstigmatizing, and may help address substantial personal and public health impact of comorbid T2DM and depression. The aim of this study was to evaluate the Web-based CBT program, myCompass, for improving social and occupational functioning in adults with T2DM and mild-to-moderate depressive symptoms. myCompass is a fully automated, self-guided public health treatment program for common mental health problems. The impact of treatment on depressive symptoms, diabetes-related distress, anxiety symptoms, and self-care behavior was also examined. Participants with T2DM and mild-to-moderate depressive symptoms (N=780) were recruited online via Google and Facebook advertisements targeting adults with T2DM and via community and general practice settings. Screening, consent, and self-report scales were all self-administered online. Participants were randomized using double-blind computerized block randomization to either myCompass (n=391) for 8 weeks plus a 4-week tailing-off period or an active placebo intervention (n=379). At baseline and postintervention (3 months), participants completed the Work and Social Adjustment Scale, the primary outcome measure. Secondary outcome measures included the Patient Health Questionnaire-9 item, Diabetes Distress Scale, Generalized Anxiety Disorder Questionnaire-7 item, and items from the Self-Management Profile for Type 2 Diabetes. myCompass users logged in an average of 6 times and completed an average of .29 modules. Healthy Lifestyles users logged in an average of 4 times and completed an average of 1.37 modules. At baseline, mean scores on several outcome measures, including the primary outcome of work and social functioning, were near to the normal range, despite an extensive recruitment process. Approximately 61.6% (473/780) of participants completed the postintervention assessment. Intention-to-treat analyses revealed improvement in functioning, depression, anxiety, diabetes distress, and healthy eating over time in both groups. Except for blood glucose monitoring and medication adherence, there were no specific between-group effects. Follow-up analyses suggested the outcomes did not depend on age, morbidity, or treatment engagement. Improvement in social and occupational functioning and the secondary outcomes was generally no greater for myCompass users than for users of the control program at 3 months postintervention. These findings should be interpreted in light of near-normal mean baseline scores on several variables, the self-selected study sample, and sample attrition. Further attention to factors influencing uptake and engagement with mental health treatments by people with T2DM, and the impact of illness comorbidity on patient conceptualization and experience of mental health symptoms, is essential to reduce the burden of T2DM. Australian New Zealand Clinical Trials Registry ACTRN12615000931572; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=368109&isReview=true (Archived by WebCite at http://www.webcitation.org/7850eg8pi).
Sections du résumé
BACKGROUND
Depressive symptoms are common in people with type 2 diabetes mellitus (T2DM). Effective depression treatments exist; however, access to psychological support is characteristically low. Web-based cognitive behavioral therapy (CBT) is accessible, nonstigmatizing, and may help address substantial personal and public health impact of comorbid T2DM and depression.
OBJECTIVE
The aim of this study was to evaluate the Web-based CBT program, myCompass, for improving social and occupational functioning in adults with T2DM and mild-to-moderate depressive symptoms. myCompass is a fully automated, self-guided public health treatment program for common mental health problems. The impact of treatment on depressive symptoms, diabetes-related distress, anxiety symptoms, and self-care behavior was also examined.
METHODS
Participants with T2DM and mild-to-moderate depressive symptoms (N=780) were recruited online via Google and Facebook advertisements targeting adults with T2DM and via community and general practice settings. Screening, consent, and self-report scales were all self-administered online. Participants were randomized using double-blind computerized block randomization to either myCompass (n=391) for 8 weeks plus a 4-week tailing-off period or an active placebo intervention (n=379). At baseline and postintervention (3 months), participants completed the Work and Social Adjustment Scale, the primary outcome measure. Secondary outcome measures included the Patient Health Questionnaire-9 item, Diabetes Distress Scale, Generalized Anxiety Disorder Questionnaire-7 item, and items from the Self-Management Profile for Type 2 Diabetes.
RESULTS
myCompass users logged in an average of 6 times and completed an average of .29 modules. Healthy Lifestyles users logged in an average of 4 times and completed an average of 1.37 modules. At baseline, mean scores on several outcome measures, including the primary outcome of work and social functioning, were near to the normal range, despite an extensive recruitment process. Approximately 61.6% (473/780) of participants completed the postintervention assessment. Intention-to-treat analyses revealed improvement in functioning, depression, anxiety, diabetes distress, and healthy eating over time in both groups. Except for blood glucose monitoring and medication adherence, there were no specific between-group effects. Follow-up analyses suggested the outcomes did not depend on age, morbidity, or treatment engagement.
CONCLUSIONS
Improvement in social and occupational functioning and the secondary outcomes was generally no greater for myCompass users than for users of the control program at 3 months postintervention. These findings should be interpreted in light of near-normal mean baseline scores on several variables, the self-selected study sample, and sample attrition. Further attention to factors influencing uptake and engagement with mental health treatments by people with T2DM, and the impact of illness comorbidity on patient conceptualization and experience of mental health symptoms, is essential to reduce the burden of T2DM.
TRIAL REGISTRATION
Australian New Zealand Clinical Trials Registry ACTRN12615000931572; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=368109&isReview=true (Archived by WebCite at http://www.webcitation.org/7850eg8pi).
Identifiants
pubmed: 31115345
pii: v21i5e12246
doi: 10.2196/12246
pmc: PMC6548532
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12246Informations de copyright
©Janine Clarke, Samineh Sanatkar, Peter Andrew Baldwin, Susan Fletcher, Jane Gunn, Kay Wilhelm, Lesley Campbell, Nicholas Zwar, Mark Harris, Helen Lapsley, Dusan Hadzi-Pavlovic, Helen Christensen, Judy Proudfoot. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 21.05.2019.
Références
Br J Psychiatry. 2018 Apr;212(4):199-206
pubmed: 30071909
Health Qual Life Outcomes. 2012 Oct 05;10:125
pubmed: 23039868
J Abnorm Psychol. 1974 Dec;83(6):651-7
pubmed: 4155711
BMC Psychiatry. 2013 Nov 18;13:312
pubmed: 24237617
J Affect Disord. 2016 May;195:119-26
pubmed: 26890289
Diabet Med. 2014 Jul;31(7):764-72
pubmed: 24606397
Diabetes Care. 2005 Mar;28(3):626-31
pubmed: 15735199
Sci Rep. 2018 May 18;8(1):7846
pubmed: 29777153
Diabetes Care. 2014 Apr;37(4):970-8
pubmed: 24198303
Med Care. 2003 Nov;41(11):1284-92
pubmed: 14583691
Acta Psychiatr Scand. 2015 Jun;131(6):465-71
pubmed: 25650176
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
J Psychosom Res. 2017 Apr;95:44-54
pubmed: 28314548
Diabetes Care. 2004 May;27(5):1047-53
pubmed: 15111519
Int J Epidemiol. 2008 Oct;37(5):941-7
pubmed: 17881411
Lancet. 2015 Aug 22;386(9995):743-800
pubmed: 26063472
Br J Psychiatry. 2002 May;180:461-4
pubmed: 11983645
Diabetes Care. 2013 Jan;36 Suppl 1:S11-66
pubmed: 23264422
J Affect Disord. 2012 Oct;142 Suppl:S8-21
pubmed: 23062861
J Clin Psychol. 2001 Apr;57(4):457-78
pubmed: 11255202
JMIR Ment Health. 2016 May 31;3(2):e23
pubmed: 27245948
JMIR Res Protoc. 2017 Aug 03;6(8):e145
pubmed: 28778848
J Health Dispar Res Pract. 2016 Fall;9(3):115-126
pubmed: 28533944
JAMA Psychiatry. 2017 Apr 1;74(4):351-359
pubmed: 28241179
Soc Psychiatry Psychiatr Epidemiol. 2012 May;47(5):827-33
pubmed: 21541696
BMC Psychiatry. 2010 Mar 21;10:25
pubmed: 20302678
Prim Care Diabetes. 2013 Apr;7(1):1-10
pubmed: 23280258
Personal Ment Health. 2017 Nov;11(4):215-228
pubmed: 28681505
Clin Psychol Rev. 2011 Dec;31(8):1239-46
pubmed: 21963669
Health Expect. 2018 Jun;21(3):668-677
pubmed: 29319923
J Med Internet Res. 2017 May 15;19(5):e157
pubmed: 28506956
Lancet Neurol. 2006 Jan;5(1):64-74
pubmed: 16361024
Diabetes Care. 2010 Jan;33(1):23-8
pubmed: 19837786
Health Aff (Millwood). 2009 May-Jun;28(3):w490-501
pubmed: 19366722
Diabetes Care. 2015 May;38(5):776-83
pubmed: 25710923
Trends Neurosci. 2012 Jan;35(1):68-77
pubmed: 22177980
Diabetes Care. 2011 Feb;34(2):320-5
pubmed: 21216855
J Psychiatr Res. 2012 Apr;46(4):549-54
pubmed: 22284972
Diabetes Care. 2014;37(3):625-33
pubmed: 24170758
Diabetes Res Clin Pract. 2010 Jan;87(1):4-14
pubmed: 19896746
Res Nurs Health. 2000 Feb;23(1):79-87
pubmed: 10686575
BMC Health Serv Res. 2010 Aug 12;10:235
pubmed: 20704720
Ann Fam Med. 2010 Jul-Aug;8(4):348-53
pubmed: 20644190
J Med Internet Res. 2005 Jun 21;7(2):e16
pubmed: 15998607
Psychosomatics. 2011 Jan-Feb;52(1):1-18
pubmed: 21300190
Curr Diab Rep. 2014 Jun;14(6):491
pubmed: 24743941
PLoS One. 2017 Oct 23;12(10):e0186473
pubmed: 29059254
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Drugs. 2015 Apr;75(6):577-87
pubmed: 25851098
Acta Psychiatr Scand Suppl. 2004;(420):47-54
pubmed: 15128387
Diabet Med. 2013 Jan;30(1):88-94
pubmed: 22924587